About Emergent BioSolutions
Emergent BioSolutions is a company based in Gaithersburg (United States) founded in 1998. The company has 900 employees. Emergent BioSolutions has completed 5 acquisitions, including ADAPT Pharma, Cangene and PaxVax. Emergent BioSolutions operates in a competitive market with competitors including Vir Biotechnology, Vaxcyte, Cidara Therapeutics, Freeline and Valneva, among others.
- Headquarter Gaithersburg, United States
- Employees 900
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website emergentbiosolutions.com
- Social LinkedIn X
- Legal Name Emergent Biosolutions Inc.
- Annual Revenue$742.9 M (USD)-28.81as on Dec 31, 2025
- Net Profit$52.6 M (USD)0as on Dec 31, 2025
- EBITDA$208.5 M (USD)288.99as on Dec 31, 2025
- Latest Funding Round$384.96K (USD), Grant
Sep 2022
- InvestorsHHS
& 5 more
- Employee Count900
- Investments & AcquisitionsADAPT Pharma
& 4 more
Funding Insights of Emergent BioSolutions
- Total Rounds 17
- Last Round Grant — $384,958
- First Round $1.81M
(Jun 2008)
- Investors Count 6
Latest 10 of 17 funding rounds of Emergent BioSolutions with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2022 | $384,958 | Grant | – | – | |
| Apr 2020 | $14.5M | Grant | – | – | |
| Feb 2020 | $32,000 | Post-IPO | – | – | |
| Sep 2019 | $6.3M | Grant | – | – | |
| Sep 2019 | $225,722 | Grant | – | – | |
| Oct 2018 | $47.87M | Post-IPO | – | – | – |
| Nov 2017 | $25,778 | Grant | – | – | |
| Oct 2017 | $200M | Post-IPO | – | – | – |
| Oct 2016 | $198.7M | Grant | – | – | |
| Jun 2012 | $2.79M | Grant | – | – |
6 investors in total: 6 institutional.
Investors in Emergent BioSolutions
Emergent BioSolutions has secured backing from 6 investors, including institutional investors. Prominent investors backing the company include HHS, European Union and Public Health Emergency.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
- | – | phe.gov | - | |
Global firm uses systematic strategies and machine learning for investment returns. | 2018 | aigen-im.com | New York, United States | |
Scientific research on drug use and addiction is supported. | – | drugabuse.gov | United States | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
- | – | niaid.nih.gov | - |
Investor details for Emergent BioSolutions
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Emergent BioSolutions
294 people are tracked at Emergent BioSolutions (119 in leadership, 10 in board & advisors, 165 in team); the tracked headcount is 900.
| Name | Role | Group |
|---|---|---|
Robert G Kramer | CEO & President | Leadership |
Jennifer Clark | Vice President, Ip, Labor & Employment, & Regulatory Legal Affairs | Leadership |
Sandra Bessette | Sr. Director, IT Business Partner, Enterprise Apps/sap | Leadership |
Kyle Carone | Director Of External Supply Operations | Leadership |
Jeff Hiebert | Director, Facility Services | Leadership |
Michael Diblasi | Director Logistics And Customer Operations | Leadership |
Ilya Blyumin | Director, Ms&t | Leadership |
Rohit Shrivastava | Director, Mfg Ops - Viral Manufacturing | Leadership |
Michael Johner | Head Of Manufacturing | Leadership |
Brian Cogan | Director Of Manufacturing Operations | Leadership |
Howard Anderson | SVP, Chief Information Officer | Leadership |
Rich League | Senior Director Information Technology, Manufacturing, Supply Chain, Quality, Pmo, And DMO | Leadership |
Darrell Odell | Director Infrastructure End User Services | Leadership |
Christy Bigelow | Vice President & General Manager | Leadership |
Kashfi A. | Senior Director, Field Operations | Leadership |
Brian Schouw | Director Operational Excellence | Leadership |
Evelyn van der Hart | Director Process Development | Leadership |
Greg Flyte | Global Head Of Manufacturing & Supply | Leadership |
Greg Comer | Director, Supply Chain | Leadership |
Dave Cassie | Director Clinical Research | Leadership |
274 more people are available in the full profile.
Complete people profiles for Emergent BioSolutions
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Emergent BioSolutions
Emergent BioSolutions is a publicly listed company on the NYSE with ticker symbol EBS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Nov 2006
- Listed onNYSE: EBS
- Listed entityEmergent BioSolutions Inc.
- Exchange sectorHealth technology
- ISINUS29089Q1058
- Share price$7.06 (+3.67% on the day) · 2026-10-09
- Market capitalisation$362.0M
- Price to earnings8.6
- EPS (diluted, trailing year)$-3.55
- Volume (last session)850,964
Financials of Emergent BioSolutions
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $742.9M | $52.6M | $208.5M |
| 2024 | $1.04B | -$190.6M | $53.6M |
| 2023 | $1.05B | -$760.5M | -$42.9M |
| 2022 | $1.12B | -$211.6M | -$10.0M |
| 2021 | $1.77B | $219.5M | $512.3M |
Detailed financial statements for Emergent BioSolutions
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Emergent BioSolutions
Emergent BioSolutions has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include ADAPT Pharma, Cangene and PaxVax.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Drugs for multiple therapeutic areas are manufactured by TEMBEXA. | tembexa.tcc.mode | – | 0 | Sep 2022 | $238M | |
Therapies for emergency conditions are developed and reformulated. | adaptpharma.com | Dublin, Ireland | 2014 | Aug 2018 | $735M | |
Oral vaccines against infectious diseases such as cholera, bird flu, HIV & others. | paxvax.com | San Diego, United States | 2007 | Aug 2018 | $270M | |
Specialization in hyperimmunes, contract manufacturing, biopharmaceuticals, and biodefense is offered. | cangene.com | Rockville, United States | 1998 | Dec 2013 | $222M | |
Antibody-like therapeutics for cancer and autoimmune diseases were developed. | trubion.com | Seattle, United States | 1999 | Aug 2010 | •••• |
Complete acquisition details for Emergent BioSolutions
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Emergent BioSolutions
9 dated milestones of Emergent BioSolutions across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Emergent BioSolutions is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.8M.
- Acquisition Acquires Trubion Pharmaceuticals.
- Acquisition Acquires Cangene.
- Acquisition Acquires PaxVax.
- Acquisition Acquires ADAPT Pharma.
- Funding Latest funding round, Grant, of $385K.
- Acquisition Acquires TEMBEXA.
Competitors of Emergent BioSolutions
Emergent BioSolutions operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Vir Biotechnology, Vaxcyte, Cidara Therapeutics, Freeline and Valneva, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. | |
| cidara.com | 2013 | San Diego, United States | $78.35M | 90 | Novel anti-infectives for bacterial and fungal infections are developed. | |
| freeline.life | 2015 | Stevenage, United Kingdom | $273.69M | 152 | Gene therapy platform is developed for chronic disease treatments. | |
| valneva.com | 1999 | Lyon, France | $113.55M | – | Prophylactic vaccines for infectious diseases are developed and advanced. | |
| seruminstitute.com | 1966 | Pune, India | – | 6,617 | Vaccines and immuno-biological drugs for infectious diseases are manufactured. | |
| biologicale.com | 1953 | Hyderabad, India | – | 6,099 | Vaccines and therapeutics for multiple diseases are developed and marketed. | |
| stridebio.com | 2015 | Durham, United States | $98.2M | 109 | AAV-based gene therapies for rare diseases are developed. | |
| redhillbio.com | 2009 | Ramat Gan, Israel | $13.5M | 183 | Developer of therapeutics for the treatment of gastrointestinal and infectious diseases | |
| osivax.com | 2017 | Lyon, France | $42.21M | – | Vaccines against mutating pathogens are developed using nanoparticle technology. |
Detailed competitors of Emergent BioSolutions
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Emergent BioSolutions
The website of Emergent BioSolutions (emergentbiosolutions.com) receives about 35.6K visits a month and ranks #745,411 among all websites worldwide, #864 in Biotechnology and Pharmaceuticals.
- Monthly visits35.6K
▼ 11.2% vs previous month
- Unique visitors19.6K
per month
- Global rank#745,411
among all websites
- Category rank#864
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit2.1
- Average visit35 sec
- DevicesDesktop 36% · Mobile 64%
Websites whose visitors overlap most with Emergent BioSolutions. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| acorda.com | 100% | – | #13,560,187 | View details | |
| endo.com | 98% | 10K | #2,323,439 | View details | |
| portola.com | 95% | – | – | View details | |
| inventivhealth.com | 95% | – | – | View details | |
| parpharm.com | 95% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 35 similar websites and full traffic analytics for Emergent BioSolutions
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 35 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Emergent Biosolutions
Complete news archive for Emergent BioSolutions
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Emergent BioSolutions
10 companies that operate in the same segment as Emergent BioSolutions (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Emergent BioSolutions
Emergent BioSolutions was founded in 1998 and raised its 1st funding round 10 years after it was founded.
Emergent BioSolutions is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Robert G Kramer is the current CEO of Emergent BioSolutions.
Emergent BioSolutions has 900 employees.
Annual revenue of Emergent BioSolutions is $742.9M as on Dec 31, 2025.
Founded in 1998 and headquartered in Gaithersburg, United States, Emergent BioSolutions operates in the biotechnology sector with a focus on vaccine development for infectious diseases. Key products include NuThrax, a combination anthrax vaccine, PreviThrax in phase 1 trials for anthrax, VAX161C for pandemic influenza, and UV-4B, an antiviral for dengue in early trials. Contract manufacturing services are also provided for bulk drug substances and sterile injectables.
Emergent BioSolutions's top competitors include Vaxcyte, Serum Institute of India and Biological E.
Yes, Emergent BioSolutions is publicly traded on NYSE under the ticker symbol EBS.
Emergent BioSolutions has made 5 acquisitions, including ADAPT Pharma, Cangene, and PaxVax.
Emergent BioSolutions has 6 investors. Key investors include HHS, European Union, Public Health Emergency, Aigen Investment Management, and National Institute on Drug Abuse.